[go: up one dir, main page]

WO2018213813A3 - Agents psychotropes et leurs utilisations - Google Patents

Agents psychotropes et leurs utilisations Download PDF

Info

Publication number
WO2018213813A3
WO2018213813A3 PCT/US2018/033552 US2018033552W WO2018213813A3 WO 2018213813 A3 WO2018213813 A3 WO 2018213813A3 US 2018033552 W US2018033552 W US 2018033552W WO 2018213813 A3 WO2018213813 A3 WO 2018213813A3
Authority
WO
WIPO (PCT)
Prior art keywords
amisulpride
enantiomer
individually
pharmaceutical composition
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/033552
Other languages
English (en)
Other versions
WO2018213813A2 (fr
WO2018213813A8 (fr
Inventor
Andrew R. VAINO
Vincent T. GRATTAN
Zachary PRENSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LB Pharmaceuticals Inc
Original Assignee
LB Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LB Pharmaceuticals Inc filed Critical LB Pharmaceuticals Inc
Priority to EP18801735.4A priority Critical patent/EP3625212A4/fr
Priority to CN201880048781.8A priority patent/CN110944630B/xx
Publication of WO2018213813A2 publication Critical patent/WO2018213813A2/fr
Priority to US16/579,545 priority patent/US11377421B2/en
Publication of WO2018213813A8 publication Critical patent/WO2018213813A8/fr
Anticipated expiration legal-status Critical
Publication of WO2018213813A3 publication Critical patent/WO2018213813A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un énantiomère R d'amisulpride et de dérivé d'amisulpride ou une composition pharmaceutique de celui-ci, qui peut être utilisé pour produire une action antagoniste sur un récepteur de sérotonine (par exemple, 5-HT2a, 5-HT7) chez un sujet, soit individuellement, soit en combinaison avec d'autres agents actifs du SNC. L'énantiomère R d'amisulpride et de dérivé d'amisulpride de l'invention ou une composition pharmaceutique de celui-ci peut être utilisée pour traiter une ou plusieurs conditions sensibles à la modulation d'un récepteur de la sérotonine (par exemple, 5-HT2a, 5-HT7) chez un sujet, soit individuellement, soit en combinaison avec d'autres agents actifs du SNC. L'énantiomère R d'amisulpride et de dérivé d'amisulpride de l'invention ou une composition pharmaceutique de celui-ci peut être utilisé pour traiter un ou plusieurs troubles associés à une anomalie dans les niveaux de sérotonine dans le cerveau, soit individuellement, soit en combinaison avec d'autres agents actifs du système nerveux central (SNC).
PCT/US2018/033552 2016-11-28 2018-05-18 Agents psychotropes et leurs utilisations Ceased WO2018213813A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18801735.4A EP3625212A4 (fr) 2017-05-18 2018-05-18 Agents psychotropes et leurs utilisations
CN201880048781.8A CN110944630B (zh) 2017-05-18 2018-05-18 精神药剂及其用途
US16/579,545 US11377421B2 (en) 2016-11-28 2019-09-23 Psychotropic agents and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508263P 2017-05-18 2017-05-18
US62/508,263 2017-05-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/383,933 Continuation-In-Part US20200079734A1 (en) 2016-11-28 2019-04-15 Psychotropic agents and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/383,933 Continuation-In-Part US20200079734A1 (en) 2016-11-28 2019-04-15 Psychotropic agents and uses thereof
US16/579,545 Continuation-In-Part US11377421B2 (en) 2016-11-28 2019-09-23 Psychotropic agents and uses thereof

Publications (3)

Publication Number Publication Date
WO2018213813A2 WO2018213813A2 (fr) 2018-11-22
WO2018213813A8 WO2018213813A8 (fr) 2019-11-07
WO2018213813A3 true WO2018213813A3 (fr) 2019-12-12

Family

ID=64274762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/033552 Ceased WO2018213813A2 (fr) 2016-11-28 2018-05-18 Agents psychotropes et leurs utilisations

Country Status (2)

Country Link
EP (1) EP3625212A4 (fr)
WO (1) WO2018213813A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968899B2 (ja) 2016-11-28 2021-11-17 エルビー・ファーマシューティカルズ・インコーポレイテッド 向精神薬およびその使用
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CA3217877A1 (fr) * 2021-05-18 2022-11-24 Lb Pharmaceuticals Inc. Agents psychotropes et leurs utilisations
CN117074579B (zh) * 2023-10-16 2023-12-22 江苏东科康德药业有限公司 一种氨磺必利口服溶液有关物质的分析方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210660A (en) * 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US6069165A (en) * 1996-09-18 2000-05-30 Synthelabo Pharmaceutical compositions containing amisulpride and their therapeutic applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968899B2 (ja) * 2016-11-28 2021-11-17 エルビー・ファーマシューティカルズ・インコーポレイテッド 向精神薬およびその使用
JP7268026B2 (ja) * 2017-12-05 2023-05-02 サノビオン ファーマシューティカルズ インク 非ラセミ混合物およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210660A (en) * 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US6069165A (en) * 1996-09-18 2000-05-30 Synthelabo Pharmaceutical compositions containing amisulpride and their therapeutic applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONAHUE J TIMOTHY: "CHARACTERIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF THE ATYPICAL ANTIPSYCHOTIC AMISULPRIDE IN C57BL/6 MICE", 12 February 2014 (2014-02-12), pages 1 - 141, XP055603263, Retrieved from the Internet <URL:https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=4609&context=etd> *

Also Published As

Publication number Publication date
WO2018213813A2 (fr) 2018-11-22
CN110944630A (zh) 2020-03-31
EP3625212A2 (fr) 2020-03-25
EP3625212A4 (fr) 2021-03-31
WO2018213813A8 (fr) 2019-11-07

Similar Documents

Publication Publication Date Title
MY205036A (en) Psychotropic agents and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JOP20190281A1 (ar) مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
WO2018213813A8 (fr) Agents psychotropes et leurs utilisations
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2021015503A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
WO2017177004A8 (fr) Amides tertiaires et procédé d&#39;utilisation
EP4603148A3 (fr) Pirfénidone enrichie en deutérium et ses procédés d&#39;utilisation
BR112021014566A2 (pt) Moduladores de gpr35
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
PH12017501736B1 (en) Indole derivatives
WO2020065090A3 (fr) Traitement de tauopathies associées à une démence

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18801735

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018801735

Country of ref document: EP

Effective date: 20191218